Future Oncology, Journal Year: 2024, Volume and Issue: 20(34), P. 2603 - 2607
Published: Aug. 28, 2024
Language: Английский
Cancer Genetics, Journal Year: 2024, Volume and Issue: 286-287, P. 18 - 24
Published: June 17, 2024
Language: Английский
Citations
98
Nature Medicine, Journal Year: 2024, Volume and Issue: 30(4), P. 1023 - 1034
Published: March 19, 2024
Abstract Gastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity dual programmed cell death protein 1 (PD-1) lymphocyte-activation gene 3 (LAG-3) inhibition may help improve immunotherapy for these tumors. We report a phase Ib trial that evaluated neoadjuvant nivolumab (Arm A, n = 16) or nivolumab–relatlimab B, in combination chemoradiotherapy 32 patients resectable stage II/stage III gastroesophageal together an in-depth evaluation pathological, molecular functional responses. Primary endpoint was safety; the secondary feasibility; exploratory endpoints included pathological complete (pCR) major response (MPR), recurrence-free survival (RFS) overall (OS). The study met its primary safety Arm although B required modification to mitigate toxicity. pCR MPR rates were 40% 53.5% A 21.4% 57.1% B. Most common adverse events fatigue, nausea, thrombocytopenia dermatitis. Overall, 2-year RFS OS 72.5% 82.6%, respectively. Higher baseline ligand (PD-L1) LAG-3 expression associated deeper Exploratory analyses circulating tumor DNA (ctDNA) showed undetectable ctDNA post-ICI induction, preoperatively postoperatively had significantly longer OS; clearance reflective neoantigen-specific T Our findings provide insights into profile combined PD-1 blockade highlight potential analysis dynamically assess systemic burden during ICI open therapeutic window future intervention. ClinicalTrials.gov registration: NCT03044613 .
Language: Английский
Citations
32
Coordination Chemistry Reviews, Journal Year: 2024, Volume and Issue: 509, P. 215786 - 215786
Published: March 20, 2024
Language: Английский
Citations
26
Journal of Molecular Neuroscience, Journal Year: 2025, Volume and Issue: 75(1)
Published: March 13, 2025
Abstract Neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s (PD), multiple sclerosis (MS), and amyotrophic lateral (ALS), are characterized by the progressive gradual degeneration of neurons. The prevalence rates these disorders rise significantly with age. As life spans continue to increase in many countries, number cases is expected grow foreseeable future. Early precise diagnosis, along appropriate surveillance, continues pose a challenge. high heterogeneity neurodegenerative diseases calls for more accurate definitive biomarkers improve clinical therapy. Cell-free DNA (cfDNA), fragmented released into bodily fluids via apoptosis, necrosis, or active secretion, has emerged as promising non-invasive diagnostic tool various diseases. cfDNA can serve an indicator ongoing cellular damage mortality, neuronal loss, may provide valuable insights processes, progression, therapeutic responses. This review will first cover key aspects then examine recent advances its potential use biomarker disorders.
Language: Английский
Citations
1
Aging and Disease, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Alzheimer's disease (AD) and disease-related disorders (ADRD) are progressive neurodegenerative diseases without cure. occurs in 2 forms, early-onset familial AD late-onset sporadic AD. Early-onset is a rare (~1%), autosomal dominant, caused by mutations presenilin-1, presenilin-2, amyloid precursor protein genes the other late-onset, prevalent evolved due to age-associated complex interactions between environmental genetic factors, addition apolipoprotein E4 polymorphism. Cellular senescence, promoting impairment of physical mental functions constituted be main cause aging, primary risk factor for AD, which results loss cognitive function, memory, visual-spatial skills an individual live or act independently. Despite significant progress understanding biology pathophysiology we continue lack definitive early detectable biomarkers and/or drug targets that can used delay development ADRD elderly populations. However, recent developments studies DNA double-strand breaks result release fragmented into bloodstream contribute higher levels cell-free (cf-DNA). This cf-DNA released from various cell types, including normal cells undergoing apoptosis necrosis elevated blood have potential serve as blood-based biomarker detection ADRD. The overall goal our study discuss latest circulating progression Our article summarized status research on both healthy states how these develop also discussed impact lifestyle epigenetic factors involved
Language: Английский
Citations
6
Frontiers in Genetics, Journal Year: 2024, Volume and Issue: 15
Published: July 9, 2024
Fundamentally precision oncology illustrates the path in which molecular profiling of tumors can illuminate their biological behavior, diversity, and likely outcomes by identifying distinct genetic mutations, protein levels, other biomarkers that underpin cancer progression. Next-generation sequencing became an indispensable diagnostic tool for diagnosis treatment guidance current clinical practice. Nowadays, tissue analysis benefits from further support through methods like comprehensive genomic liquid biopsies. However, medicine field presents specific hurdles, such as cost-benefit balance widespread accessibility, particularly countries with low- middle-income. A key issue is how to effectively extend next-generation all patients, thus empowering decision-making. Concerns also quality preservation samples, well evaluation health technologies. Moreover, technology advances, novel assessments are being developed, including study Fragmentomics. Therefore, our objective was delineate primary uses sequencing, discussing its’ applications, limitations, prospective paths forward Oncology.
Language: Английский
Citations
6
Cancer Discovery, Journal Year: 2024, Volume and Issue: 15(1), P. 105 - 118
Published: Sept. 30, 2024
Abstract Ovarian cancer is a leading cause of death for women worldwide, in part due to ineffective screening methods. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome and protein biomarker [cancer antigen 125 (CA-125) human epididymis 4 (HE4)] analyses evaluate 591 with ovarian cancer, benign adnexal masses, or without lesions. Using machine learning model the combined features, detected specificity >99% sensitivities 72%, 69%, 87%, 100% stages I IV, respectively. At same specificity, CA-125 alone 34%, 62%, 63%, 100%, HE4 28%, 27%, 67%, cancers Our approach differentiated masses from high accuracy (AUC = 0.88, 95% confidence interval, 0.83–0.92). These results were validated an independent population. findings show that integrated cfDNA detect performance, enabling new accessible noninvasive diagnostic evaluation. Significance: There unmet need effective approaches enable earlier-stage detection increased overall survival. We have developed high-performing evaluates fragmentomes biomarkers cancer.
Language: Английский
Citations
5
The Journal of Liquid Biopsy, Journal Year: 2023, Volume and Issue: 2, P. 100126 - 100126
Published: Nov. 7, 2023
Liquid biopsies have emerged as groundbreaking tools for minimally invasive monitoring of cancer, encompassing the analysis Cell-Free DNA (cfDNA), circulating tumor (ctDNA) and exosomes. This paradigm shift offers an emerging approach understanding dynamics, treatment responses, disease progression. Leveraging advancements in molecular biology technology, liquid enable clinicians to gain intricate insights from peripheral blood, thereby transforming landscape cancer care. review describes clinical impact, technological innovations, recent evidence surrounding integration ctDNA exosome monitoring. Through early detection, real-time response assessment, tracking minimal residual disease, redefined standards precision oncology. Key analysis, such high-throughput sequencing digital PCR, empower detection actionable mutations with high sensitivity. Concurrently, characterization exosomal cargo, facilitated by next-generation mass spectrometry, unveils nuances tumors. Recent studies underscore utility these approaches, demonstrating their efficacy predicting relapse, guiding therapeutic decisions, ultimately improving patient outcomes. As field continues evolve, hold promise not only diagnostic but also agents personalized medicine, enabling precise navigation invasiveness.
Language: Английский
Citations
12
Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 203, P. 104483 - 104483
Published: Aug. 17, 2024
Language: Английский
Citations
4
Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)
Published: Oct. 21, 2024
Abstract Circulating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determine the cfDNA tumor fraction validate method in two independent cohorts patients colorectal or lung cancer. DELFI-TF scores strongly correlate circulating levels (ctDNA) (r = 0.90, p < 0.0001, Pearson correlation) even cases where mutations are undetectable. therapy initiation associated clinical response predictors overall survival (HR 9.84, 95% CI 1.72-56.10, 0.0001). Patients lower during treatment have longer (62.8 vs 29.1 months, HR 3.12, 1.62-6.00, 0.001) predicts outcomes more accurately than imaging. These results demonstrate potential fragmentomes estimate burden outcome prediction.
Language: Английский
Citations
4